Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Asensus Surgical's Sloan Ratio for the quarter that ended in Mar. 2024 was -138.51%.
Warning Sign:
When sloan ratio (-134.23)% higher than 25% or lower than -25%, earnings are more likely to be made up of accruals.
As of Mar. 2024, Asensus Surgical has a Sloan Ratio of -138.51%, indicating earnings are more likely to be made up of accruals.
Asensus Surgical Sloan Ratio % Historical Data
The historical data trend for Asensus Surgical's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Asensus Surgical's Sloan Ratio %
For the Medical Devices subindustry, Asensus Surgical's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Asensus Surgical's Sloan Ratio % Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Asensus Surgical's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Asensus Surgical's Sloan Ratio % falls into.
Asensus Surgical Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Asensus Surgical's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Asensus Surgical's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was -19.071 (Jun. 2023 ) + -17.164 (Sep. 2023 ) + -15.804 (Dec. 2023 ) + -20.697 (Mar. 2024 ) = €-72.74 Mil.
Asensus Surgical's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 was -16.573 (Jun. 2023 ) + -14.101 (Sep. 2023 ) + -12.264 (Dec. 2023 ) + -12.887 (Mar. 2024 ) = €-55.83 Mil.
Asensus Surgical's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 was 6.059 (Jun. 2023 ) + 19.469 (Sep. 2023 ) + 6.811 (Dec. 2023 ) + 2.76 (Mar. 2024 ) = €35.10 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asensus Surgical (FRA:2TX) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Mar. 2024, Asensus Surgical has a Sloan Ratio of -138.51%, indicating earnings are more likely to be made up of accruals.
Asensus Surgical Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of Asensus Surgical's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Asensus Surgical Inc is a medical device company that digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through digital laparoscopy. It enables the use of advanced capabilities such as augmented intelligence, connectivity, and robotics in laparoscopy and seeks to address the current clinical, cognitive, and economic shortcomings in surgery. The Senhance Surgical System is the first machine vision system for use in robotic surgery, which is powered by the new Intelligent Surgical Unit that enables augmented intelligence in surgery and brings the benefits of digital laparoscopy to patients around the world. The company's single segment includes the research, development, and sale of medical device robotics to improve minimally invasive surgery.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:2TX has been successfully added to your 